UK-based GW Pharma (GWPH) is allowing long-term investors a good entry today following the release of Q1 results and a conference call that followed. The stock continued to retrace a good portion of its massive rally in early January today but has reversed:
Today's low was just above 70, but the stock lifted off of those levels quickly and has gotten back above the lows set near 72 last week and going into the number:
The report from the company as well as the conference call didn't really add too much new information. GWPH will be spending aggressively this year to move along several candidates in Phase 2 or Phase 3 clinical trials, and we should expect a lot of data throughout the year. On the call, the company suggested that it may present some data on Epidiolex, its drug under development to treat rare childhood epilepsy, at the April meeting of the American Academy of Neurology. Furthermore, management shared anecdotal evidence that Epidiolex may not only help control seizures, but it may also help improve quality of life in these patients in other ways. The company believes that the drug may prove helpful to patients with autism.
The big picture summary of today's report and conference call are that there are no changes to the cash flow guidance provided in December, the company continues to advance its rich pipeline and that Epidiolex remains the key but not exclusive part of that pipeline. The company will be sharing a significant amount of data as the year progresses on both Epidiolex as well as Sativex and other pipeline candidates.
Taking a longer-term perspective, GWPH, which at $72 is worth about $1.44 billion, has not only solid fundamentals in terms of a huge war chest ($240mm) to fund its many opportunities along ...